CTLA4 and non-small cell lung carcinoma: Here, we collected five cohorts of SKCM patients (1 MAGE - A3 and 4 CTLA-4 and PD-1 blockade immunotherapy) and two cohorts of NSCLC patients who received PD-1 blockade immunotherapy.